Pharmacogenetics and pharmacogenomics in rheumatology

Szekanecz, Z. and Mesko, B. and Póliska, Szilárd and Vancsa, A. and Szamosi, S. and Vegh, E. and Simkovics, E. and Laki, J. and Kurko, J. and Besenyei, T. and Mikecz, K. and Glant, T. and Nagy, László (2013) Pharmacogenetics and pharmacogenomics in rheumatology. IMMUNOLOGIC RESEARCH, 56 (2-3). pp. 325-333. ISSN 0257-277X

Text Pharmacogenetics and pharmacogenomics in rheumatology.pdf Restricted to Repository staff only Download (251kB) | Request a copy

Abstract

Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and Fc gamma R genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

Actions (login required)

Edit Item